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OBJECTIVES: To evaluate the effect of the intraoperative use of hydroxyethyl starch on the need for blood
products in the perioperative period of oncologic surgery. The secondary end-points included the need for
other blood products, the clotting profile, the intensive care unit mortality and length of stay.
METHODS: Retrospective observational analysis in a tertiary oncologic ICU in Brazil including 894 patients
submitted to oncologic surgery for a two-year period from September 2007. Patients were grouped according
to whether hydroxyethyl starch was used during surgery (hydroxyethyl starch and No-hydroxyethyl starch
groups) and compared using a propensity score analysis. A total of 385 propensity-matched patients remained
in the analysis (97 in the No-hydroxyethyl starch group and 288 in the hydroxyethyl starch group).
RESULTS: A higher percentage of patients in the hydroxyethyl starch group required red blood cell transfusion
during surgery (26% vs. 14%; p=0.016) and in the first 24 hours after surgery (5% vs. 0%; p=0.015) but not in
the 24- to 48-hour period after the procedure. There was no difference regarding the transfusion of other
blood products, intensive care unit mortality or length of stay.
CONCLUSION: Hydroxyethyl starch use in the intraoperative period of major oncologic surgery is associated
with an increase in red blood cell transfusions. There are no differences in the need for other blood products,
intensive care unit length of stay or mortality.
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& INTRODUCTION
Fluid expansion is critical during surgery and in post-
operative care. The ideal fluid type (crystalloids or colloids)
and the optimum dosage of fluids are much debated issues
(1-4). Hydroxyethyl starches (4) are widely used as fluid
expanders in the perioperative period and are the preferred
colloids in many intensive care units (ICU) (5,6).
Hydroxyethyl starch (HES) may impair blood coagulation
by reducing the levels of von Willebrand factor and factor
VIII and by decreasing the platelet count and function (7-
10). It has been suggested that the new generation HES
(third generation, low molecular weight, low degree of
substitution) is less prone to cause blood coagulation
disorders than the old compounds (11), but this issue
remains controversial (7,12,13) primarily because few
studies evaluated the issue (4). In the perioperative period,
even the new generation starches inspire concerns about
their safety, especially in terms of coagulation disorders
(1,7,13-15).
Patients submitted to oncologic surgery are subjected to
long surgery procedures, with a great need of fluid
resuscitation and blood products transfusion. It has been
suggested that surgical cancer patients are more prone to
being transfused with blood products than non-cancer
patients (16). No study has evaluated the effects of the
intraoperative use of a new generation HES on the
intraoperative and postoperative red blood cells and other
blood products transfusion in patients submitted to elective
major oncologic surgery.
We hypothesized that patients submitted to oncologic
surgery that received a new generation HES during surgery
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would require more red blood cells transfusions during and
after the surgery than patients that did not receive HES. To
test our hypothesis, we evaluated whether a new generation
HES led to more red blood cell transfusions during the first
48 hours after major elective oncologic surgery than patients
that received only crystalloids using a propensity-matched
approach. Secondary objectives included clotting profile,
use of blood products other than red cells, ICU length of
stay and mortality between the two groups.
& PATIENTS AND METHODS
Study design: Retrospective analysis of medical records.
Patients: The Ethics Committee of the Hospital AC
Camargo approved this study and waived patient consent
due to its retrospective observational nature. From
September 2007 to September 2009, all patients admitted
to the hospital ICU (three units with a total of 33 beds) of
our teaching hospital after an elective major oncologic
surgery (head and neck, neurological, thoracic, abdominal
and other sites) were included in the study.
Data collection: In the hospital, all data are recorded in a
computerized physician order entry and an electronic
medical record system. We collected the data recorded
during the surgery and the following 48 hours. During the
intraoperative period, we collected the number of packs of
blood products transfused (red blood cells, fresh frozen
plasma, platelets and cryoprecipitate), the surgery length
and the volume of crystalloids and colloids infused. During
ICU admission, we collected the simplified acute physiol-
ogy score 3 (SAPS 3) and performed laboratory exams that
included creatinine levels and clotting profile (composed of
the platelets count and prothrombin time (PT)). During the
48-hour period after the surgery, we collected the number of
packages of blood products transfused and performed
laboratory exams, including serum creatinine. We divided
the 48-hour period after the surgery into two periods of 24
hours because the hypothetical HES side effect could be
evanescent. The data were analyzed for three consecutive
periods: the intraoperative period, the period from the end
of the surgery to the first 24 hours after post-surgery (24-
hour period) and the period between from 24 to 48 hours
after the surgery (24- to 48-hour period). The patients were
categorized in two groups according to the use of HES
during the intraoperative period (HES and No-HES group).
The patients in the HES group received at least 500 mL of
new generation HES (VoluvenH - 6% 130/0.4, Fresenius,
Germany).
Perioperative transfusion policy: The hospital transfusion
policy recommends that patients should be admitted to the
operating room with a hemoglobin level greater than
10 mg/dL and platelet count above 50 6 103 units/mL.
Coagulation disorders, as assessed by aPTT and PT, were
treated with preoperative fresh frozen plasma transfusion
until both values were within the normal range (interna-
tional normalized ratio and aPTT ratio less or equal to 1.5).
Other causes of coagulopathy, such as vitamin K deficiency,
were assessed as appropriate. Blood transfusion during
surgery is left to the discretion of the anesthesiologist and
surgeon. All anesthesiologists in the hospital are part of a
small team that follows protocols for surgery resuscitation
and blood transfusion. There are five major surgical teams
in the hospital (thoracic, abdominal, pelvic, neurological
and soft tissue) and each has a closed staff, i.e., surgery at
each specific site is usually performed by a very restricted
number of surgeons. The ICU policy for transfusion
suggests that red blood cell packs should be transfused if
the hemoglobin level is below 7 g/dL or below 8 g/dL with
signs of active bleeding and/or impaired tissue perfusion
(delayed capillary refill time, elevated lactate levels and
nonchloremic metabolic acidosis) (17). Transfusion with
hemoglobin levels above 9 g/dL was not encouraged and
was performed only at the discretion of the intensivist if
massive blood lost was detected (high output in the drain
with hemodynamic instability). Platelets were transfused if
the total count was less than 506103 units/mL with active
bleeding or after neurosurgery. Cryoprecipitate transfusion
was indicated in patients with fibrinogen levels less than
100 mg/dL. Fresh frozen plasma was administered if the
coagulation times were two-fold higher the normal value
range in patients with active bleeding or after neurosurgery.
Colloid use policy: At the time of the study, the only
synthetic colloid available at our institution was a new
generation 6% HES 130/0.4 (VoluvenH). HES was adminis-
tered at the discretion of the anesthesiologist during
surgery. HES use on the ICU postoperative period is not
part of our postoperative resuscitation protocol and is
discouraged. Albumin was not used during the post-
operative period of elective oncologic surgery.
Statistical analysis: Categorical and continuous data are
presented as percentages and the mean ¡ SD (or median
and 25%-75% interquartile range [IQR]), respectively.
Categorical variables were compared using the Chi-square
or Fisher exact test, as appropriate. Quantitative continuous
variables were compared using an unpaired t test or Mann-
Whitney test for parametric or nonparametric variables,
respectively.
Patients were clustered according to the administration of
HES during surgery. Because the use of colloids was not
randomized, there were two unbalanced groups (Table 1).
Because this was a retrospective analysis (patients were not
randomized), the creation of a propensity score is an
effective method to reduce bias. Propensity-matched ana-
lyses are increasingly being used in research due to its
ability to improve the power of retrospective and prospec-
tive non-randomized analysis (18,19). Propensity score has
been defined as the ‘‘condition probability of being treated
given the covariates’’ (20). Propensity-matched analyses are
able to take into account as many variables related to the
outcome evaluated as needed, which reduces bias (20).
To construct the propensity score, a logistic regression
was fitted, and variables were chosen for inclusion accord-
ing to the methods of Brookhart et al. (18). We included
variables that could be related to the study outcomes based
on the propensity score. To identify the variables potentially
associated with the outcome, a univariate analysis was
performed to evaluate potential variables related to blood
transfusion during the entire perioperative period (from the
surgical procedure to up to 48 hours after surgery). The
variables included on the propensity score were as follows:
age, gender, body-mass index, metastatic disease, surgery
length, volume of crystalloid infused and surgical sites.
Although age and body mass index were not associated
with the outcome, we believed that they were important
variables that could alter the fluid dynamics during the
surgical procedures and included them in the model (21).
The best caliper was 0.05, which was obtained by the Austin
method (22). After the propensity score was created, the
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patients were matched according to their respective
propensity scores. As reported in the current literature,
matching on the propensity score has now been clearly
demonstrated to be the best method to attempt to provide
an unbiased estimation of the treatment effect (19). First,
based on the crude analysis, we pre-defined a match
considering one patient without HES use to a maximum
of three patients with HES use. The match procedure was
performed with an optimal matching method, and to avoid
overinflation, we did not permit replacement of matched
patients. The number of patients analyzed using the
propensity score was smaller than the total number of
patients studied because matching was not possible for all
patients. Our analysis was performed with fewer patients
than the original study population. Even with fewer
patients, an analysis using the propensity score is more
reliable than traditional statistical methods because imbal-
ance between groups is reduced (18,23). The correct
construction of the propensity score was performed with
the box-plot method. After the propensity score matches
were performed, we performed a diagnostic to ensure good
balance in the matched population through the bias
reduction method and the stabilized standardized differ-
ence (because we were using 1:N matching instead of 1:1
matching) (19,22). After matching, the groups were com-
pared using conventional statistical tests.
We performed an additional analysis using ‘‘corrected
total volume’’ (CTV) instead of crystalloid volume as a
variable in the propensity score (see Appendix). CTV was
defined as total crystalloid volume60.3 plus 1.46 infused
colloid volume (21,24,25). This alternative analysis was
conducted to balance the effective volume used for
expansion in both groups (see Appendix for details). All
the statistical analysis were performed in SPSS 19.0, and a p-
value of 0.05 for was considered significant for all
comparisons.
& RESULTS
We included 894 patients; 614 received HES, and 280
received only crystalloids during surgery. Before the use of
the propensity score, the patients in the HES group had
longer surgical times, had received more crystalloids, were
younger and were less likely to have any comorbidity
compared with the No-HES group (Table 1). There were
also differences regarding the surgery site between groups.
After the creation of the matched groups, 385 propensity-
matched patients (97 in the crystalloids group and 288 in the
HES group) were analyzed. Patients in the paired groups
had similar baseline characteristics (Table 1). The median
volume of infused HES was 1 L [0.5-1.0]. No patient
received less than 0.5 L. Creatinine values were similar for
both groups in all the observation periods. The incidence of
acute kidney injury (AKI) (defined according to the RIFLE
criteria of risk, i.e., an increase of serum creatinine of 50% or
more over the baseline) (26,27) was similar between the
groups (7% versus 7%, p.0.99). More detailed results
regarding the other propensity matched analysis (using
CTV), standard logistic regression and non-propensity
matched results analysis can be found in the Appendix.
Red blood cells and other blood products transfusions:
The variables related to transfusion of red blood cell pack
transfusion for all the perioperative transfusions are shown
in Table 2. Most patients in both groups did not require
blood products transfusion. In the HES group, a higher
percentage of patients received red blood cell transfusion in
the intraoperative and 24-hour postoperative period, but the
percentage was similar for the 24- to 48-hour postoperative
period (Figure 1). For the patients in both groups that
received red blood cell transfusions, the number of packs
per patient was higher in the HES group during the
intraoperative period (0.55 versus 0.39; p= 0.028). No patient
in the No-HES group received a blood transfusion after
surgery. There was no difference regarding the use of fresh
frozen plasma, cryoprecipitate and platelets concentrate in
any period.
The patients that received HES had a small but
statistically significant lower hemoglobin level at ICU
admission (11.2¡1.9 versus 12.0¡1.7; p,0.001) but not at
the 24-hour (11.1¡1.8 versus 11.3¡1.6; p= 0.11) and 48-hour
(10.2¡1.7 versus 10.2¡1.5; p= 0.20) postoperative periods.
Table 1 - Baseline characteristics of the patients that received hydroxyethyl starch (HES group) and crystalloid during
major oncologic surgery.
Overall data Propensity-matched
No-HES (n = 280) HES (n= 614) p-value No-HES (n= 97) HES (n= 288) p-value
Age, years 61¡16 57¡16 ,0.001 59¡17 58¡16 0.54
Male, n (%) 136 (49) 316 (52) 0.42 48 (50) 143 (50) 0.98
SAPS 3 46¡13 47¡11 0.43 46¡14 46¡12 0.97
BMI, kg/m2 26¡6 26¡5 0.94 27¡5 26¡5 0.66
Metastatic disease, n (%) 85 (31) 187 (31) 0.98 31 (32) 85 (30) 0.65
Any chronic comorbidity, n (%) 242 (86) 475 (77) 0.002 79 (81) 227 (79) 0.58
Total operative time, hours 3 (2-5) 6.2 [5-8.5] ,0.001 5 (3-6) 5 [4-6.2] 0.14
Crystalloid volume received, L 2.0 [1.0-2.5] 4.5 [3.0-6.5] ,0.001 3 [2.0-4.5] 3.5 [2.0-4.5] 0.18
HES volume received, L 0 1 [0.5-1.1] 0 1 [0.5-1.0]
Site of surgery ,0.001 0.23
Abdominal 128 (46) 458 (74) ,0.001 57 (59) 195 (68) 0.11
Head and neck 50 (18) 73 (12) 0.016 8 (8) 29 (10) 0.60
Central nervous system 49 (17) 45 (7) ,0.001 14 (14) 37 (13) 0.69
Thoracic 27 (10) 30 (5) 0.007 12 (12) 20 (7) 0.09
Soft tissue 21 (7) 6 (1) ,0.001 4 (4) 5 (2) 0.24
Other 5 (2) 2 (1) 0.034 2 (2) 2 (1) 0.26
BMI = body mass index; HES = hydroxyethyl starch; SAPS 3 = simplified acute physiology score 3.
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The transfusion rate was similar between the groups
when we employed the propensity analysis that included
CTV (Additional Table 2). The results of the non-propensity
analysis (see Appendix, Additional Table 3 and 4) showed
that red blood cell transfusion was more frequent in the HES
patients. The multivariate analysis showed that the factors
associated with red blood cell transfusion in the periopera-
tive period included age, metastatic disease, total operative
time, crystalloid volume used and colloid use (any dose).
Thoracic and head and neck surgery were protective factors
against transfusion (see Additional Table 5).
Secondary objectives: Patients in the HES group showed
lower levels of platelets at ICU admission compared to the
No-HES group (Table 3). The international normalized ratio
(INR) was also higher in the HES patients at ICU admission
and in the first 24 hours after surgery (Table 3). Table 4
shows the coagulation values for transfused and non-
transfused patients in both groups (No-HES and HES).
The INR was higher in transfused No-HES patients than in
non-transfused No-HES patients. The INR was also higher
in the transfused HES patients than the non-transfused HES
patients at ICU admission. There were no differences
between transfused patients in the HES and No-HES groups
regarding platelet count or INR at any period studied. Non-
transfused HES patients also had a higher INR than non-
transfused No-HES patients.
ICU mortality and length of stay were similar between
HES and No-HES groups (Table 3).
& DISCUSSION
In this retrospective analysis using a propensity-matched
cohort of surgical patients, HES use was associated with
more frequent red blood cells transfusions during major
oncologic surgery and in the first 24 hours after the
procedure. ICU length of stay and mortality were the same
for both groups.
There is an intense debate involving HES use in critically ill
patients. HES are considered more efficient volume expan-
ders than crystalloids; i.e., less volume is needed to obtain the
same hemodynamic effect (28,29). A recent randomized
controlled trial suggested that patients with penetrating
trauma required less total volume when resuscitated by HES
compared with saline; there was no difference, however, in
patients with blunt trauma (30). A recently published trial in
septic patients suggested that less fluid was needed to reach
hemodynamic stability in patients resuscitated with HES
(31). A larger multicenter randomized trial has shown no
difference regarding the total fluid need in septic patients
(24). The need for less fluid to obtain the same hemodynamic
effect would be particularly interesting during the intrao-
perative period, when hemodynamic optimization associated
with less total fluid volume may be beneficial (32).
HES and other colloids are not related to any robust positive
clinical outcome, such as mortality or reduced ICU length of
stay (33). In the recently published 6S Trial, septic patients that
were randomized to fluid resuscitation with HES had higher
mortality, suggesting that at least in this specific population,
HES use should be strongly discouraged (24). The doubtful
greater efficiency of HES may be counteracted by significant
side effects, including coagulation abnormalities and AKI (13).
The impact of these side effects on outcome, especially forHES
6% 130/0.4, is largely unknown (4).
Oncologic patients may have coagulation abnormalities
related to their illness and chemotherapy side effects (34).
We aimed to evaluate the effects of HES on the periopera-
tive need for blood transfusion in this specific population.
This outcome is important because blood transfusion may
be associated with worse outcome after oncologic surgery,
including long-term survival (35-38). Blood transfusion is
not harmless and has been associated with several clinical
side effects, including transfusion related acute lung injury
and fluid overload (39). In critically ill patients, blood
transfusion is associated with poorer outcomes (39).
Our propensity-matched data showed that HES use is
independently related to a greater need for red blood cell
transfusion in the perioperative period. As previously
reported, even low doses of HES could result in coagulation
abnormalities (14). In addition to requiring more red blood
cell transfusions, HES patients also had lower hemoglobin
levels at ICU admission, suggesting that the difference was
not only due to over transfusion of the HES group.
Figure 1 - Percentage of patients that received red blood cell
transfusion on each studied period.
Table 2 - Univariate analysis of factors related to red
blood cell transfusion.
Perioperative RBC
transfusion
No (n=624) Yes (n = 270) p-value
Age, years$ 58¡16 58¡15 0.73
Male, n (%)$ 329 (53) 123 (46) 0.049
SAPS 3 45¡12 49¡11 ,0.001
BMI, kg/m2 $ 27¡6 26¡5 0.069
Metastatic disease, n (%)$ 168 (27) 106 (39) ,0.001
Any chronic comorbidity, n (%) 505 (81) 212 (79) 0.41
Total operative time, hours$ 5 (3-7) 7 (5-9) ,0.001
Crystalloid volume received, L$ 3.0 [1.6-4.5] 5.5 [4.0-7.1] ,0.001
HES volume received, L 0.5 [0.0-1.0] 1.0 [0.5-1.5] ,0.001
Site of surgery$ ,0.001
Abdominal 379 (60) 207 (77)
Head and neck 96 (15) 27 (10)
Central nervous system 75 (12) 19 (7)
Thoracic 50 (8) 7 (3)
Soft tissue 20 (3) 7 (3)
Other 4 (1) 3 (1)
BMI = body mass index; HES = hydroxyethyl starch; SAPS 3 = simplified
acute physiology score 3; $ = variables included in the propensity-score.
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Corroborating with our results, other studies have shown a
higher need for blood products in critically ill patients who
received HES (24,40). Patients with blunt trauma resusci-
tated with HES required more blood transfusions than
patients who received saline, although this conclusion is
likely confounded by a higher injury severity in the HES-
resuscitated patients (30). Our standard multivariate analy-
sis showed that colloid use was a risk factor for the
perioperative need for red blood cell transfusion. When we
performed the CTV analysis, both groups had similar
transfusion rates. Nevertheless, because this analysis
included fewer patients (with only 41 patients in the No-
HES group – see Appendix), it is possible that the smaller
sample reduced the power of the study to detect any
difference.
It can be argued that because the use of HES is associated
with a greater degree of plasma volume expansion, and
considering that the two groups were paired to the crystal-
loid volume infused, our findings may be related only to the
increased hemodilution caused by HES use (41). The
increase in the frequency of red blood cell pack transfusions
in the HES group in the main propensity analysis might to
some degree be related to the expansion effect of HES and
not to its impact on blood coagulation. The lack of difference
in the CTV analysis corroborates this hypothesis. It should
be stated that the effectiveness of HES as a dilutional agent
appears to be reduced after major injury (42) and that our
patients also used a small volume of starch that was below
the suggested maximum daily dose of 50 mL/kg.
There were small differences in the coagulation profile
between the HES and No-HES groups. Those differences are
likely without clinical significance because the values were
very similar between the groups (Table 3). There were no
differences in the coagulation profile (including the INR and
platelet count) between the transfused patients in both groups
(Table 4). The higher need for transfusions cannot be explained
by the differences in coagulation features after surgery.
In our multivariate analysis, thoracic surgery was a
protector factor against transfusion. It may be speculated
that because restrictive fluid therapy is frequently used in
thoracic surgery (43), patients received less fluid, with less
hemodilution and bleeding related to dilutional coagulo-
pathy, and therefore required less red blood cell transfusion.
The ICU length of stay and mortality were similar
between groups, but our analysis was likely underpowered
to detect a significant difference in a population with low
mortality (below 2%) and short ICU length of stay (one day
of median ICU stay). In the univariate analysis, ICU length
of stay was higher in the HES group than in the No-HES
group (Additional Table 6).
There are several limitations in our analysis. First, this
study has a single-center retrospective analysis design.
Table 3 - Secondary objectives.
No-HES n=97 HES n=288 p-value
ICU mortality and LOS
ICU mortality, n (%) 1 (1) 6 (2) 0.69
ICU LOS, days [IQ] 1 (1-2) 1 (1-2) 0.48
Clotting profile
Platelet count at ICU admission 219 [165-293]6 103 191 [141-239]6103 0.003
Platelet count at the 24-hour postoperative period 200 [153–262]6 103 193 [142–250]6 103 0.22
Platelet count during the 24- to 48-hour postoperative period 190 [143–302]6 103 188 [135–235]6 103 0.24
PT (INR) at ICU admission 1.12 [1.06-1.21] 1.19 [1.10-1.29] ,0.001
PT (INR) at the 24-hour postoperative period 1.16 [1.07-1.25] 1.19 [1.10-1.31] 0.027
PT (INR) during the 24- to 48-hour postoperative period 1.29 [1.17-1.37] 1.27 [1.14-1.41] 0.94
PT = prothrombin time; INR = international normalized ratio; ICU = intensive care unit; LOS = length of stay.
Table 4 - Characteristics of the transfused and non-transfused patients in the HES and No-HES groups.
No-HES HES
Comparison between
No-HES and HES
No-Tx (n= 85) Tx (n = 12) p No-Tx (n = 207) Tx (n= 81) p No-Tx Tx
Age, years 59 ¡ 17 65 ¡ 12 0.22 58 ¡ 16 58 ¡ 16 0.94 0.87 0.17
Male, n (%) 43 (51) 5 (42) 0.27 108 (52) 35 (43) 0.11 0.44 0.65
SAPS 3 45 ¡ 14 54 ¡ 11 0.040 45 ¡ 11 48 ¡ 11 0.040 0.81 0.13
Metastatic disease, n (%) 22 (26) 9 (75) 0.011 55 (26) 30 (37) 0.12 0.96 0.047
Platelets count at ICU admission 215 [170-285]
6103
207 [129-289]
6103
0.56 200 [149-251]
6103
173 [124-245]6103 0.12 0.034 0.42
Platelet count at the 24-hour
postoperative period
201 [155–265]
6103
188 [122–250]
6103
0.38 200 [155–258]
6103
180 [112–266]
6103
0.17 0.60 0.91
Platelet count during the 24- to
48-hour postoperative period
182 [143–314]
6103
191 [100–232]
6103
0.39 190 [155–258]
6103
158 [109–239]6103 0.021 0.68 0.81
PT (INR) at ICU admission 1.11 [1.06-1.18] 1.18 [1.15-1.25] 0.007 1.15 [1.08-1.25] 1.24 [1.14-1.40] ,0.001 0.003 0.31
PT (INR) at the 24-hour
postoperative period
1.15 [1.06-1.23] 1.18 [1.13-1.45] 0.15 1.18 [1.09-1.27] 1.20 [1.11-1.33] 0.18 0.11 0.95
PT (INR) during the 24- to 48-hour
postoperative period
1.24 [1.06-1.36] 1.30 [1.27-1.32] 0.69 1.28 [1.14-1.42] 1.27 [1.15-1.39] 0.60 0.44 0.76
TX = red blood cell pack transfusion; BMI = body mass index; HES = hydroxyethyl starch; SAPS 3 = simplified acute physiology score 3.
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Second, the propensity score analysis was unable to match
for unmeasured variables. Third, due to its retrospective
nature, we were unable to control for personal preferences
variables regarding red blood cell transfusion and specific
tumor staging (which could be related to technical difficul-
ties during the surgical procedure), although we included
metastatic disease in the propensity score. Fourth, although
our hospital has strict policies for transfusion and perio-
perative fluid therapy, we cannot guarantee that these
protocols were followed in all of the patients analyzed.
Triggers for transfusion were also unavailable for analysis.
Fifth, our study was underpowered to evaluate the ICU
length of stay and mortality.
Our finding that HES use is associated with a greater need
for blood transfusion is biologically plausible and has been
reported in other clinical scenarios (24,40). If these findings
are confirmed in large, prospective studies, HES use should
be questioned in the subjects undergoing elective oncologic
surgery due to its unproven clinically efficacy over crystal-
loids (4,13). The surgical procedures on oncologic patients
have specific aspects that need further study.
The intraoperative use of HES 6% 130/0.4 during major
elective oncologic surgery is associated with an increase in
red blood cell transfusions in the perioperative period of
major oncologic surgery. There were no differences in ICU
length of stay and mortality. Further randomized clinical
trials in this specific population are urgently needed.
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& APPENDIX
Results of propensity score using corrected total
volume and the results of standard multivariate
analysis
Impact of intraoperative HES 6% 130/0.4 on the need for
blood transfusion after major oncologic surgery: A propen-
sity-matched analysis
Corrected total volume (CTV) analysis: Our propensity
score analysis using CTV instead of infused crystalloid
volume resulted in 97 patients in the No-HES group and 162
patients in the HES group. The major difference between
this analysis and the previous analysis was the use of the
corrected total volume (CTV) as a variable instead of the
volume of infused crystalloid. We sought to minimize
the role of hemodilution as a trigger to transfusion; i.e., the
propensity-matched patients in this analysis would have
received the same amount of plasma expansion. Because the
expansion effects of colloids are different from crystalloids,
we created a variable that would account for the corrected
amount of fluid expansion received (CTV). We defined the
CTV in patients in the No-HES group as equivalent to the
crystalloid volume infused multiplied by 0.3 (1). The CTV in
the HES group was defined as the sum of the crystalloid
volume multiplied by 0.3 plus the volume of HES
multiplied by 1.4 (CTV = [crystalloid volume6 0.3] + [1.4
6 colloid volume]). The use of the 1.4 ratio aimed at
accounting for the theoretical greater expansion effects of
the colloids (2,3).
This alternative propensity analysis included 41 patients
in the No-HES group and 118 patients in the HES group
(Additional Table 1). There was no difference in the need for
red blood cell transfusion between the groups when this
analysis was performed (Additional Table 2). The interna-
tional normalized ration (INR) was higher at ICU admission
in the HES group, but the other coagulation variables were
similar (Additional Table 3).
Study results of standard analysis: The second approach
was a standard multivariate logistic regression. The
stepwise backward method was used to determine the
factors associated with red blood cell transfusion in the
perioperative time. The initial model consisted of all of the
independent variables that had a p value of less than 0.25 in
the bivariate analysis associated with red cell blood
transfusion or between the HES and non-HES groups in
the 894 patients (the Hosmer-Lemeshow logistic regression).
The variables were removed one at a time if they did not
contribute to the model assessed according to a likelihood
ratio test (p, 0.050). The continuous variables were checked
for the assumption of linearity in the logit. Single colinea-
rity was evaluated with Pearson’s correlation between the
independent variables, and multi-colinearity was evaluated
with the variance inflation factor. The odds-ratios and
Additional Table 1 - CTV propensity score analysis.
No-HES (n= 41) HES (n= 118) p-value
Age, years 61¡14 57¡17 0.19
Male, n (%) 18 (44) 66 (56) 0.18
SAPS 3 49¡19 47¡13 0.52
BMI, kg/m2 27¡4 26¡5 0.22
Metastatic disease, n (%) 13 (32) 39 (33) 0.87
Any chronic comorbidity, n (%) 33 (81) 91 (77) 0.65
Total operative time, hours 5.0 [3.8-6] 6.0 [4.0-7.0] 0.10
CTV, L 1.4 [1.1-1.8] 1.9 [1.3-3.2] 0.51
Site of surgery 0.69
Abdominal 26 (63) 82 (70)
Head and neck 3 (7) 13 (11)
Central nervous system 4 (10) 10 (9)
Thoracic 6 (15) 9 (8)
Soft tissue 2 (5) 3 (3)
Other 0 1 (1)
Legend: BMI = body mass index; HES = hydroxyethyl starch; SAPS 3 = simplified acute physiology score 3; CTV = corrected total volume.
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corresponding 95% confidence intervals for each variable
were computed. The discriminative ability of the model to
predict the outcome of patients was assessed by the area
under the receiver operating characteristic (AUC) curve.
The calibration ability for the model was evaluated with
Hosmer-Lemeshow goodness-of-fit statistics.
The major outcomes regarding the need for blood
transfusion on crude analysis are displayed in
Additional Table 4. The major difference between pro-
pensity-matched versus standard analysis was that before
matching, the need for blood products other than red
blood cell packs was more common in the HES patients.
The HES patients in the unmatched analysis received
fresh frozen plasma during surgery more frequently than
the No-HES patients. The need for cryoprecipitate was
also more frequent in the HES patients in the first 24 hours
after the procedure.
A multivariate analysis was performed to evaluate the
risk factors for red blood cell transfusion from the
intraoperative period up to 48 hours after the procedure
(Additional Table 5). The factors associated with the red
blood cell transfusions included age, metastatic disease,
volume of crystalloid used, total operative time and use of
any dose of HES. These factors may only highlight that
patients that received blood transfusion were subject to
more aggressive and/or technically difficult surgeries. Head
and neck and thoracic surgery were protectors against
transfusion.
The ICU length of stay was higher in the HES group
(Additional Table 6).
Additional Table 2 - Main study outcomes of the CTV propensity analysis.
No-HES (n= 41) HES (n = 118) p-value
Intraoperative period
Patients that received red blood cells, (%) 10 (24) 32 (27) 0.73
Patients that received fresh frozen plasma, (%) 4 (10) 1 (1) 0.016
Patients that received platelets, (%) 0 0 -
Patients that received cryoprecipitate, (%) 0 2 (2) .0.99
24 h postoperative period
Patients that received red blood cells, (%) 0 5 (4) 0.33
Patients that received fresh frozen plasma, (%) 0 0 -
Patients that received platelets, (%) 0 1 (1) .0.99
Patients that received cryoprecipitate, (%) 0 3 (2) 0.55
24-48 h postoperative period
Patients that received red blood cells, (%) 0 1 (1) .0.99
Patients that received fresh frozen plasma, (%) 0 0 -
Patients that received platelets, (%) 0 0 -
Patients that received cryoprecipitate, (%) 0 0 -
Combined intraoperative and postoperative periods
Patients that received red blood cells in the intraoperative and first 24 hours, (%) 10 (24) 35 (30) 0.52
Patients that received red blood cells in the intraoperative and first 48 hours, (%) 10 (24) 36 (31) 0.46
HES = hydroxyethyl starch.
Additional Table 3 - Secondary objectives of the CTV propensity analysis.
No-HES n=41 HES n=118 p-value
ICU mortality and LOS
ICU mortality, n (%) 0 2 (2) .0.99
ICU LOS, days [IQ] 2 (1-3) 1 (1-2) 0.89
Clotting profile
Platelet count at ICU admission 207 [154-285]6 103 203 [141-2253]6 103 0.22
Platelet count at the 24-hour postoperative period 202 [156–256]6103 212 [156–266]6 103 0.85
Platelet count during the 24- to 48-hour postoperative period 163 [141–233]6103 192 [136–242]6 103 0.76
PT (INR) at ICU admission 1.16 [1.10-1.24] 1.17 [1.09-1.31] 0.36
PT (INR) at the 24-hour postoperative period 1.15 [1.11-1.23] 1.22 [1.13-1.31] 0.04
PT (INR) during the 24- to 48-hour postoperative period 1.30 [1.24-1.38] 1.32 [1.19-1.46] 0.97
PT = prothrombin time; INR = international normalized ratio; ICU = intensive care unit; LOS = length of stay.
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Additional Table 4 - Transfusion outcomes according to standard univariate analysis.
Transfusion outcomes No-HES (n = 280) HES (n = 614) p-value
Intraoperative period, patients that received blood fraction, n (%)
Red blood cells 24 (9) 216 (35) ,0.001
Fresh frozen plasma 7 (3) 38 (6) 0.019
Platelets 0 0 1
Cryoprecipitate 0 0 1
24-hour postoperative period, patients that received blood fraction, n (%)
Red blood cells 7 (3) 46 (8) 0.003
Fresh frozen plasma 6 (2) 24 (4) 0.174
Platelets 2 (1) 7 (1) 0.73
Cryoprecipitate 0 16 (3) 0.004
24- to 48-hour postoperative period, patients that received blood fraction, n (%)
Red blood cells 4 (1) 24 (4) 0.061
Fresh frozen plasma 2 (1) 2 (1) 0.59
Platelets 0 2 (1) 1.00
Cryoprecipitate 0 1 (1) 1.00
Combined intraoperative and postoperative periods
Intraoperative period and up to 24 hours after the procedure, patients that received blood fraction, n (%)
Red blood cells 28 (10) 231 (38) ,0.001
Fresh frozen plasma 11 (4) 53 (9) 0.011
Platelets 2 (1) 7 (1) 0.73
Cryoprecipitate - 16 (3) 0.004
Intraoperative period and up to 48 hours after the procedure, patients that received blood fraction, n (%)
Red blood cells 31 (11) 239 (39) ,0.001
Fresh frozen plasma 12 (4) 53 (9) 0.020
Platelets 2 (1) 9 (2) 0.52
Cryoprecipitate - 17 (3) 0.002
Additional Table 5 - Multivariate model to predict red
blood cell package transfusion on intraoperative and
perioperative times (up to 48 hours).
Betta OR (95% CI) p-value
Agea 0.012 1.129 (1.018-1.252) 0.021
Metastatic cancer 0.633 1.883 (1.350-2.625) ,0.001
Thoracic surgery -1.296 0.274 (0.118-0.637) 0.003
Head and neck surgery -0.627 0.534 (0.319-0.895) 0.017
Total operative timec, hours 0.811 2.250 (1.459-3.470) ,0.001
Crystalloid volume receivedc, l 0.652 1.919 (1.079-3.413) 0.026
Colloid 0.857 2.355 (1.471-3.772) ,0.001
aper 10 units increase;
bcompared with other sites of surgery;
cper 01 log increase.
Model performance:
Hosmer-Lemeshow goodness of fitness test: Chi-square 11.664; p=0.167.
AUC: 0.752 (95% CI: 0.717-0.786); p,0.001.
Additional Table 6 - Outcomes in the standard univariate
analysis.
Outcome Non-HES (n =280) HES (n= 614) p-value
ICU mortality, n(%) 4 (1) 13 (2) 0.60
ICU LOS, days [IQ] 1 (1-2) 2 (1-3) ,0.001
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